Reagent and kit for detecting methylation level of molecular marker and application of reagent and kit

By detecting the methylation level of CpG sites in a specific genomic region, the problem of insufficient sensitivity and specificity of early screening methods for liver cancer is solved, and a non-invasive and accurate liver cancer screening method is provided, which improves the accuracy of early diagnosis. and patient survival rate.

CN118910263AInactive Publication Date: 2024-11-08GUANGZHOU YOUZE BIOLOGICAL PHARM TECH CO LTD +1

Patent Information

Application Number
CN202411167390.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-23
Publication Date
2024-11-08
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

The existing early screening methods for liver cancer have low sensitivity and specificity, which is difficult to meet the needs of early diagnosis, and common imaging examinations have radiation hazards and high cost problems.

Method used

By detecting the methylation level of CpG sites in the chr2:63053864-63054353 region, a non-invasive, convenient, safe and fast methylation level detection reagent is used to distinguish between patients with primary hepatocellular carcinoma and benign liver diseases. and healthy people.

Benefits of technology

High sensitivity and specific screening and auxiliary diagnosis of primary hepatocellular carcinoma have been achieved, the accuracy of early liver cancer screening has been improved, and the incidence and mortality of liver cancer have been reduced.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118910263A_ABST
    Figure CN118910263A_ABST
Patent Text Reader

Abstract

The invention discloses a reagent and a kit for detecting methylation level of a molecular marker and application of the reagent and the kit, and belongs to the technical field of gene detection. By detecting the methylation level of the CpG site in the chr2: 63053864-63054353 region (taking an hg38 genome as a reference genome), whether a target is a primary hepatocellular carcinoma patient or not can be identified. The detection area shows a high methylation level for patients with primary hepatocellular carcinoma, and the detection area shows a low methylation level for patients with liver diseases and healthy people. Detection of the methylation level of the CpG loci in the region has good sensitivity and specificity for screening and auxiliary diagnosis of the primary hepatocellular carcinoma, and can be used for distinguishing samples of patients with the primary hepatocellular carcinoma from samples of patients with liver benign diseases (liver cirrhosis, hepatitis and the like) and samples of healthy people.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the technical field of gene detection, and in particular relates to a reagent and a kit for detecting the methylation level of a molecular marker and an application thereof. Background Art

[0002] Primary liver cancer (PHC) is the sixth most common cancer in the world, the second most common cause of cancer death in the world, the fourth most common malignant tumor and the second most common cause of cancer-related death. In recent years, its incidence has been on the rise worldwide. It is estimated that by 2025, 1 million people worldwide will suffer from liver cancer each year. Since the early symptoms of primary liver cancer are not obvious, it is often in the middle or late stages when diagnosed, and the opportunity for surgery is lost. Epidemiological data show that there are 90 million hepatitis B virus carriers, and the number of liver cancer cases accounts for 54% of the world's total. Every year, 370,000 patients die from liver cancer. Liver cancer is a public health issue that seriously threatens people's lives and health.

[0003] The liver is hidden deep in the upper abdomen, and it is difficult to detect enlargement in the early stage. At the same time, the liver has a strong compensatory ability. In the early stage, there are often no symptoms or the symptoms are not obvious. Patients usually only show non-specific digestive tract symptoms, such as loss of appetite, nausea, vomiting, etc., so it is difficult to diagnose in the early stage. There are 855,000 new cases of primary liver cancer in the world each year, and 810,000 deaths from primary liver cancer in the world each year. The 5-year survival rate of liver cancer patients is 30.1% in Japan, 27.2% in South Korea, and 17.4% in the United States. The prognosis of hepatocellular carcinoma is related to the severity of the disease at the time of diagnosis. Because of late discovery, only 25% of patients with newly diagnosed liver cancer can undergo surgical resection. 85% of patients with newly diagnosed liver cancer are already in the middle and late stages. Because the early symptoms of hepatocellular carcinoma are not obvious, they are often diagnosed in the middle and late stages and lose the opportunity for surgery. Early screening, early diagnosis and early treatment are effective ways to reduce the incidence and mortality of hepatocellular carcinoma. Convenient, safe, fast and high-throughput screening methods are particularly important.

[0004] Currently, ultrasound combined with serum alpha-fetoprotein (AFP) testing is the most widely used liver cancer screening technology, but the sensitivity and specificity of AFP are only 58.2% and 85.3%, which is difficult to meet the clinical needs of early screening and diagnosis of hepatocellular carcinoma.

[0005] The current hepatocellular carcinoma diagnosis and treatment guidelines recommend that high-risk groups undergo liver ultrasound examinations and serum alpha-fetoprotein (AFP) tests every 6 months for early screening of liver cancer. Alpha-fetoprotein AFP is a widely used primary liver cancer tumor marker. When it is greater than 400μg / L or the content continues to rise, it has a definite diagnostic significance. However, about 40% of patients with small liver cancer (liver cancer with a diameter of less than 3 cm) have normal alpha-fetoprotein levels. At the same time, non-malignant diseases, such as acute and chronic hepatitis, recovery from severe hepatitis, cirrhosis, and congenital bile duct occlusion, can also cause elevated alpha-fetoprotein. Therefore, according to relevant research statistics, the sensitivity of serum alpha-fetoprotein AFP testing alone for early liver cancer diagnosis is about 32% to 49%, which is relatively low. Color Doppler ultrasound combined with serum alpha-fetoprotein testing can increase the sensitivity of liver cancer diagnosis to about 63%, but the sensitivity is still low. Other imaging examinations such as CT or MRI are radioactive, and multiple tests are harmful to human health and costly. In actual application, imaging examinations are easily affected by many factors such as lesion size, machine sensitivity and operator level. In addition, fine needle aspiration biopsy and other invasive operations have low patient compliance.

[0006] There is still a need in this field for an accurate early liver cancer diagnosis method that is non-invasive, low-cost, highly sensitive and specific, and suitable for large-scale screening to popularize early liver cancer screening and improve the accuracy of early screening. Summary of the invention

[0007] The object of the present invention is to provide a reagent for detecting the methylation level of a molecular marker. The inventors have verified that the reagent can identify whether the target is a patient with primary hepatocellular carcinoma by detecting the methylation level of CpG sites in the chr2:63053864-63054353 region (with the hg38 genome as the reference genome). The detection region shows a high methylation level in patients with primary hepatocellular carcinoma, and a low methylation level in patients with liver disease and healthy people. Detecting the methylation level of CpG sites in the above-mentioned region has good sensitivity and specificity for screening and auxiliary diagnosis of primary hepatocellular carcinoma, and can be used to distinguish samples of patients with primary hepatocellular carcinoma from patients with benign liver diseases (cirrhosis, hepatitis, etc.) and samples of healthy people.

[0008] The present invention provides a non-invasive, convenient, safe, fast and highly accurate methylation level detection reagent for the screening and auxiliary diagnosis of primary hepatocellular carcinoma.

[0009] The present invention is achieved through the following technical solutions:

[0010] A reagent for detecting the methylation level of a molecular marker, wherein the molecular marker is a nucleic acid molecule containing at least one CpG site in the chr2:63053864-63054353 genomic region sequence;

[0011] The genomic regions are from the hg38 human reference genome.

[0012] Preferably, the molecular marker is located in the following regions containing at least one CpG site: region 1, region 2, region 3, region 4, region 5, region 6;

[0013] The region 1 is selected from chr2: 63053874-63053971; the region 2 is selected from chr2: 63053953-63054107; the region 3 is selected from chr2: 63053970-63054089; the region 4 is selected from chr2: 63054088-63054212; the region 5 is selected from chr2: 63054112-63054305; the region 6 is selected from chr2: 63054194-63054326.

[0014] Preferably, the reagent includes any one of a nucleic acid combination 1 for detecting the area 1, a nucleic acid combination 2 for detecting the area 2, a nucleic acid combination 3 for detecting the area 3, a nucleic acid combination 4 for detecting the area 4, a nucleic acid combination 5 for detecting the area 5, and a nucleic acid combination 6 for detecting the area 6.

[0015] Preferably, the nucleic acid combination 1 includes primer combination 1, the nucleic acid combination 2 includes primer combination 2, the nucleic acid combination 3 includes primer combination 3, the nucleic acid combination 4 includes primer combination 4, the nucleic acid combination 5 includes primer combination 5, and the nucleic acid combination 6 includes primer combination 6;

[0016] The base sequence of the primer combination 1 has at least 90% identity with the base sequence shown in SEQ ID NO.1-2;

[0017] The base sequence of the primer combination 2 has at least 90% identity with the base sequence shown in SEQ ID NO.4-5;

[0018] The base sequence of the primer combination 3 has at least 90% identity with the base sequence shown in SEQ ID NO.7-8;

[0019] The base sequence of the primer combination 4 has at least 90% identity with the base sequence shown in SEQ ID NO.10-11;

[0020] The base sequence of the primer combination 5 has at least 90% identity with the base sequence shown in SEQ ID NO.13-14;

[0021] The base sequence of the primer combination 6 has at least 90% identity with the base sequence shown in SEQ ID NO.16-17.

[0022] Preferably, the nucleic acid combination 1 further includes probe 1, the nucleic acid combination 2 further includes probe 2, the nucleic acid combination 3 further includes probe 3, the nucleic acid combination 4 further includes probe 4, the nucleic acid combination 5 further includes probe 5, and the nucleic acid combination 6 further includes probe 6;

[0023] The base sequence of the probe 1 has at least 90% identity with the base sequence shown in SEQ ID NO.3;

[0024] The base sequence of the probe 2 has at least 90% identity with the base sequence shown in SEQ ID NO.6;

[0025] The base sequence of the probe 3 has at least 90% identity with the base sequence shown in SEQ ID NO.9;

[0026] The base sequence of the probe 4 has at least 90% identity with the base sequence shown in SEQ ID NO.12;

[0027] The base sequence of the probe 5 has at least 90% identity with the base sequence shown in SEQ ID NO.15;

[0028] The base sequence of the probe 6 has at least 90% identity with the base sequence shown in SEQ ID NO.18.

[0029] A detection product for non-diagnostic purposes of primary hepatocellular carcinoma, the detection product comprising the reagent.

[0030] Preferably, the detection product further comprises any one of a kit, a chip and a sequencing library.

[0031] In a preferred embodiment of the present invention, the 5' end of the probe is labeled with a fluorescent group, and the 3' end of the probe is labeled with a fluorescent quenching group.

[0032] The fluorescent reporter group is HEX, FAM, TET, CF532, JOE, TAMRA, ROX, CY3, CY5, Texas Red, NED, Alexa Flour or VIC, and the quencher group is MGB, TAMRA, BHQ1, BHQ2, BHQ3 or QSY.

[0033] The reagent can be in the form of freeze-dried powder, solution, suspension, emulsion, etc.

[0034] A detection kit for non-diagnostic purposes of primary hepatocellular carcinoma comprises the nucleic acid combination of the CpG island site, a positive control substance, a negative control substance, a detection primer of an internal reference gene, a detection probe of an internal reference gene, a DNA polymerase and a buffer.

[0035] Preferably, the detection sample of the kit is an ex vivo blood sample or an ex vivo tissue sample and an ex vivo leukocyte sample.

[0036] Compared with the prior art, the present invention has at least the following technical effects:

[0037] (I) The present invention provides a reagent for detecting the methylation level of a molecular marker, which can identify whether the target is a primary hepatocellular carcinoma patient by detecting the methylation level of CpG sites in the chr2:63053864-63054353 region (with the hg38 genome as the reference genome).

[0038] The detection area shows high methylation level in patients with primary hepatocellular carcinoma, and low methylation level in patients with liver disease and healthy people. Detecting the methylation level of CpG sites in the above region has good sensitivity and specificity for the screening and auxiliary diagnosis of primary hepatocellular carcinoma, and can be used to distinguish samples from patients with primary hepatocellular carcinoma from patients with benign liver diseases (cirrhosis, hepatitis, etc.) and healthy people.

[0039] (ii) The present invention provides a non-invasive, convenient, safe, fast and highly accurate methylation level detection reagent for the screening and auxiliary diagnosis of primary hepatocellular carcinoma.

[0040] (3) The hg38 genome is used as the reference genome. By detecting the methylation rate of specific regions on the genome, it can be determined whether the sample is primary liver cancer.

[0041] (IV) The use of the detection product can distinguish liver cancer samples from normal healthy human samples, and in some embodiments, liver cancer and benign liver disease can be distinguished. At the same time, the above-mentioned methylation sites can be used for high-sensitivity screening of early liver cancer.

[0042] (V) This kit is a methylation marker with good sensitivity and specificity for early screening of liver cancer. It can conveniently, quickly and inexpensively perform early screening of liver cancer samples. It can also increase the early diagnosis rate of HCC high-risk groups, improve the early survival rate of HCC patients, and reduce morbidity and mortality. BRIEF DESCRIPTION OF THE DRAWINGS

[0043] Figure 1 is a research and development flow chart of mining and screening of methylation markers for detecting liver cancer in Example 1;

[0044] Figure 2 This is the ROC diagram of the detection of the methylation marker in Example 3 in the ex vivo blood sample of liver cancer. DETAILED DESCRIPTION

[0045] The embodiments of the present invention will be described in detail below in conjunction with examples. However, those skilled in the art will understand that the following examples are only used to illustrate the present invention and should not be construed as limiting the scope of the present invention. The specific conditions not specified in the examples are carried out according to conventional conditions or conditions recommended by the manufacturer. The reagents or instruments used without indicating the manufacturer are all conventional products that can be purchased commercially.

[0046] A technical solution of a specific implementation of the present invention is:

[0047] The terms "complementary" and "complementarity" refer to deoxynucleotides / ribonucleotides (e.g., 1 base) or polydeoxynucleotides / ribonucleotides (e.g., base sequences) associated with base pairing rules. For example, sequence 5'-TAT-3 is complementary to sequence 3-ATA-5. Complementarity can be "partial", in which only some nucleic acid bases are matched according to base pairing rules. Alternatively, there may be "complete" complementarity between nucleic acids, and the degree of complementarity between nucleic acid chains affects the binding efficiency of hybridization between primers and nucleic acid sequences and probes and nucleic acid sequences.

[0048] The term "chain polymerase reaction" is used to amplify the target sequence. The method consists of the following steps: adding a large amount of excess primers to the DNA mixture reaction system with the desired target sequence, followed by a precise thermal cycle reaction in the presence of a DNA chain polymerase. Through the principle of "partial" complementarity or "full" complementarity between the primer and the template chain, denaturation-complementary sequence annealing-extension and multiple rounds of repeated thermal reactions are carried out according to the reaction procedure to obtain a high concentration of amplified fragments of the desired target sequence. Due to the repetitive aspect of the method, the method is called "polymerase chain reaction" ("PCR"). Its product is a "PCR product" or "amplicon". Therefore, the present invention includes but is not limited to the nucleic acid detection and determination method of DNA sequencing method, probe hybridization method, methylation-specific high-performance liquid chromatography method, ddPCR method, methylation-specific high-resolution melting curve method, methylation-specific microarray method, methylation-sensitive restriction endonuclease method and Methylight method.

[0049] The term "methylation level" refers to any measured value used to determine the methylation state of one or more CpG dinucleotide sequences within a nucleic acid sequence. The methylation state can optionally be represented by a "methylation level" by comparing the Ct value of the amplification curve after the bisulfite reaction, or by comparing the sequences of bisulfite-treated and untreated nucleic acids. It can be used as a quantitative indicator of methylation levels in multiple copies. The degree of co-methylation is represented or indicated by the methylation state of more than one methylation site. In a methylated region, co-methylation is defined when the methylation state of more than one methylation site is methylated.

[0050] Example 1: Screening process for liver cancer detection methylation markers, such as Figure 1 As shown,

[0051] This embodiment discloses a methylation marker composition for detecting early liver cancer and a screening process thereof.

[0052] In order to mine and screen methylation markers with excellent detection performance, this example first uses a customized hybrid capture large panel for targeted methylation sequencing. The hybrid capture panel covers 3.98 million CpG methylation sites in the human genome, including most of the CpG island regions and genes related to cancer occurrence, with a coverage range 10 times that of traditional DNA methylation chips. By performing targeted sequencing on 82 clinical frozen tissue samples and 115 ex vivo blood samples and comparing the changes in methylation patterns of cancer and non-cancer groups, this example preliminarily identified 30,008 methylation sites that can clearly distinguish cancer and non-cancer samples in both tissue and blood samples as potential cancer markers.

[0053] Furthermore, a hybrid capture panel was designed based on the 30,008 methylation sites initially screened above for a second round of targeted methylation sequencing. This round of sequencing adopted a deep sequencing strategy, with an average sequencing depth of 500X, which significantly improved the accuracy of methylation level calculations and facilitated the accurate screening of markers in the second round. Targeted methylation sequencing was performed on ex vivo plasma samples from 218 clinical liver cancer patients and 196 ex vivo plasma samples from non-cancer groups, and 12 DNA methylation markers with the best liver cancer detection performance were accurately screened using univariate statistical analysis and machine learning methods.

[0054] Finally, the primer and probe nucleic acid combination of the qPCR detection platform was designed for the genomic regions of the 12 methylation markers screened, and the performance of liver cancer detection was verified on the qPCR platform through the in vitro plasma samples of 32 clinical liver cancer patients and 47 in vitro plasma samples of non-cancer groups. Finally, the DNA methylation marker with the best performance in liver cancer detection was determined through univariate performance analysis, namely the methylation level of the chr2:63053864-63054353 genomic region.

[0055] The primer combination for detecting the methylation level of the marker includes any one of SEQ ID NO.1-2, SEQ ID NO.4-5, SEQ ID NO.7-8, SEQ ID NO.10-11, SEQ ID NO.13-14 and SEQ ID NO.16-17.

[0056] The nucleic acid probe used for detection includes any one of SEQ ID NO.3, SEQ ID NO.6, SEQ ID NO.9, SEQ ID NO.12, SEQ ID NO.15 and SEQ ID NO.18.

[0057] Example 2: Detection performance of the screened markers in liver cancer tissue samples

[0058] 33 clinical samples of liver cancer tissue and 49 non-cancer control tissue samples were collected. The tissue samples were subjected to genome extraction, enzyme-based methylation conversion, and targeted methylation sequencing. The specific experimental steps are as follows:

[0059] 1. DNA sample extraction: When the sample is a frozen fresh tissue sample, use QIAGEN's " The genome was extracted using Blood & Tissue Kit #69506. For specific operations, please refer to the kit instructions. Genomic DNA was sheared using a Covaris M220 ultrasonic shearer. When cfDNA was extracted from plasma samples, Guangzhou Youze Biotechnology's Free DNA Extraction Kit (Filtration Method) #C02-1 was used. For specific operations, please refer to the kit instructions.

[0060] 2. Use SPRIselect magnetic beads to screen the extracted DNA samples according to the recommended steps in the instructions, and filter out DNA molecules larger than 200 bp.

[0061] 3. Preparation of quality control products: 10 μL of 0.1 ng / μL CpG methylated pUC19 and 10 μL of 2 ng / μL unmethylated λ DNA should be added to each sample;

[0062] 4. Library construction for methylation sequencing: Use the NEBNext Enzymatic Methyl-Seq kit to construct the library.

[0063] 4.1 End repair and 3′ end addition of “A”

[0064] 4.1.1 Take 50 ng of the sample to be tested, dilute it to 50 μL with NF water, and then add the following reagents for reaction.

[0065] Components Volume (μL) Control DNA working solution 20 End repair reaction solution 5 End Repair Enzyme Mix 5

[0066] 4.1.2 Place in PCR instrument and perform reaction according to the following procedure

[0067]

[0068] 4.2 Connector connection

[0069] 4.2.1 Add the following reagents to the end repair product for reaction

[0070] Components Volume (μL) EM-seq Ligation Adapter Solution 5 Connection Enhancer 5 Ligation Mix 50

[0071] 4.2.2 Place in a PCR instrument and set the PCR reaction program according to the following conditions: 60°C, 60 min, with the heated lid closed.

[0072] 4.2.3 Purification of adapter ligation products

[0073] A. Equilibrate the purified magnetic beads at room temperature for 30 minutes and thoroughly mix them on a vortex.

[0074] B. Prepare 80% ethanol according to the ratio of anhydrous ethanol to nuclease-free water = 8:2 and set aside.

[0075] C. Add 55 μL of purified magnetic beads to each ligation product, mix well by pipetting, incubate at room temperature for 5 minutes, place on a magnetic rack, and discard the supernatant after the solution is clarified; wash with freshly prepared 80% ethanol, discard the supernatant, and repeat this step once; dry, elute with 15 μL of elution buffer, and aspirate 14 μL of supernatant for the next reaction.

[0076] 4.3 Methylation: Oxidation reaction

[0077] 4.3.1 Configure buffer:

[0078] a. Add 400 μL of E1 reaction buffer to 100 μL of E1 reaction buffer supplement, shake and mix, and mark the preparation date.

[0079] b. Take 10 μL of 500 mM Fe(Ⅱ) and add it to 1249 μL of nuclease-free water. Use the diluted solution immediately. It should be used immediately after preparation and cannot be stored.

[0080] cDilute the Stop Buffer 1:10 with nuclease-free water.

[0081] 4.3.2 Add the following reagents to 14 μL of purified ligation product and mix well, then add

[0082] Components Volume (μL) Remark Prepared TET2 reaction solution 5 Dissolved E1 supplement solution Oxidation supplement reaction solution 0.5 - Dithiothreitol 0.5 - Oxidation Enhancement Fluid 10 - E1 2 -

[0083] After the oxidase is purified, 10 μL of diluted Fe(Ⅱ) is added to the ligated product, mixed and centrifuged.

[0084] 4.3.3 Place in PCR instrument and react under the following conditions: 37℃, 1h, heating cover temperature ≥ 45℃.

[0085] 4.3.4 After the reaction is completed, add 1 μL of diluted reaction stop solution to the product and place it on the PCR instrument for reaction under the following conditions: 37°C, 30 min, hot cover temperature ≧45°C.

[0086] 4.3.5 Purification of oxidation reaction products

[0087] A. Equilibrate the purified magnetic beads at room temperature for 30 minutes and thoroughly mix them on a vortex machine;

[0088] B. Prepare 80% ethanol in a ratio of 8:2, and set aside.

[0089] C. Add 45 μL of NEB Next Sample purified magnetic beads to each ligation product, mix well by pipetting, incubate at room temperature for 5 minutes, place on a magnetic rack, and discard the supernatant after the solution is clarified; wash with freshly prepared 80% ethanol, discard the supernatant, and repeat this step once; dry, elute with 9.5 μL elution buffer, and aspirate 8 μL of supernatant for the next reaction.

[0090] 4.4 Methylation: cytosine deamination

[0091] 4.4.1 Denaturation:

[0092] a. Preheat the PCR instrument to 85°C and open the heated cover;

[0093] b. Add 2 μL of formamide to 8 μL of the purified oxidation reaction product, vortex to mix, and centrifuge briefly.

[0094] 4.4.2 Add the following reagents to the denatured product for reaction

[0095] Components Volume (μL) Nuclease-free water 34 E2 reaction solution 5 BSA 0.5 E2 0.5

[0096] 4.4.3 Place in PCR instrument and react under the following conditions: 37℃, 3h, heating cover temperature ≥ 45℃.

[0097] 4.4.4 Purification of Cytosine Deamination Reaction Products

[0098] a. Equilibrate the purified magnetic beads at room temperature for 30 min and thoroughly mix them on a vortex machine;

[0099] b. Prepare 80% ethanol according to the ratio of anhydrous ethanol to nuclease-free water = 8:2 and set aside;

[0100] c. Add 50 μL of NEB Next Sample purified magnetic beads to each ligation product, mix well by pipetting, incubate at room temperature for 5 minutes, place on a magnetic rack, and discard the supernatant after the solution is clarified; wash with freshly prepared 80% ethanol, discard the supernatant, and repeat this step once; dry, elute with 11 μL of elution buffer, and aspirate 10 μL of supernatant for the next reaction.

[0101] 4.5 PCR amplification and purification

[0102] 4.5.1 Add the following reagents to the above purified product for reaction

[0103] Components Volume (μL) Primers 2.5 Enzyme mixture 12.5

[0104] 4.5.2 Place on PCR instrument and react according to the following conditions

[0105]

[0106] 4.5.3 Purification of PCR amplification products

[0107] a. Equilibrate the purified magnetic beads at room temperature for 30 min and thoroughly mix them on a vortex machine;

[0108] b Prepare 80% ethanol in a ratio of 8:2 for use;

[0109] c. Add 22.5 μL of NEB purified magnetic beads to each ligation product, mix well by pipetting, incubate at room temperature for 5 minutes, place on a magnetic rack, and discard the supernatant after the solution is clarified; wash with freshly prepared 80% ethanol, discard the supernatant, and repeat this step once; dry, elute with 15 μL of elution buffer, aspirate 14 μL of supernatant, and perform quality inspection.

[0110] 5. Hybridization and elution

[0111] 5.1 Hybridization:

[0112] a Take 10 ng of each library to be hybridized, calculate the library volume required for combined hybridization, and mix the 12 libraries together;

[0113] b. Add the following reagents to the library mixture for reaction;

[0114] c. Turn on the vacuum concentrator, set the V-AQ mode, and concentrate into dry powder at room temperature;

[0115] d. Immediately take 20 μL of hybridization mixture and add it to the concentrated dry powder, mix well and let it stand at room temperature for 5 minutes, then add 30 μL of hybridization enhancement solution, mix well and centrifuge;

[0116] e was placed on a PCR instrument and reacted according to the following conditions.

[0117] Reagent composition table

[0118] Components Volume (μL) Liver cancer probe 2 Internal reference probe 2 Universal blocking solution 8 Blocking reaction solution 5

[0119] PCR reaction conditions table

[0120]

[0121] 5.2 Capture and elution

[0122] 5.2.1 buffer preheating:

[0123] Preheat the rapid binding solution and rapid washing solution 2 at 48°C until the precipitate is dissolved, and preheat the rapid washing solution 1 at 63°C until the precipitate is dissolved. Equilibrate the streptavidin magnetic beads at room temperature for at least 30 minutes.

[0124] 5.2.2 Magnetic Bead Capture

[0125] a Vortex to mix the streptavidin magnetic beads that have been equilibrated to room temperature;

[0126] b. Take 70 μL of streptavidin magnetic beads and add them into a 1.5 mL centrifuge tube;

[0127] c. Add 20 μL of binding buffer, mix by pipetting, centrifuge briefly, place on a magnetic stand, let stand for 1 min, and discard the supernatant;

[0128] d. Repeat steps b and c twice, performing streptavidin magnetic bead washing three times in total;

[0129] e. Add 20 μL binding buffer to resuspend the streptavidin magnetic beads;

[0130] f Transfer 20 μL of resuspended streptavidin magnetic beads to the hybridization reaction tube, and then transfer all the liquid to a 1.5 mL centrifuge tube.

[0131] g. Mix on a mixer at room temperature for 30 minutes without vortexing.

[0132] After mixing, centrifuge immediately, place on a magnetic rack, let stand for 1 minute, and discard the supernatant.

[0133] 5.2.3 Elution

[0134] a. Add 200 μL of 54°C preheated rapid wash buffer 1, mix well by pipetting, and incubate in a thermostatic metal bath at 54°C for 5 min;

[0135] b After the incubation is completed, centrifuge briefly and transfer all the liquid to a new 1.5 mL centrifuge tube to remove the non-specific capture fragments bound to the surface of the centrifuge tube;

[0136] c Place on a magnetic stand, let stand for 1 minute, and discard the supernatant;

[0137] d. Add 200 μL of washing buffer 1 preheated at 63°C, mix well by pipetting, and incubate in a thermostatic metal bath at 54°C for 5 minutes;

[0138] eAfter incubation, centrifuge immediately, place on a magnetic stand, let stand for 1 min, and discard the supernatant;

[0139] f. Add 200 μL of 54°C preheated washing buffer 2, pipette to mix, and incubate in a thermostatic metal bath at 54°C for 5 minutes;

[0140] After the incubation is completed, centrifuge immediately, place on a magnetic stand, let stand for 1 minute, and discard the supernatant;

[0141] h. Repeat steps a to g twice for a total of three washes;

[0142] i Centrifuge briefly, discard the remaining supernatant with a 10 μL pipette tip, immediately add 45 μL of nuclease-free water, mix by pipetting, and incubate on ice.

[0143] 5.3 PCR enrichment of capture products

[0144] 5.3.1 Take 22.5 μL of the captured product (streptavidin magnetic bead suspension) and add the following reagents to react.

[0145]

[0146]

[0147] Place on PCR instrument and react according to the following conditions

[0148]

[0149] 5.3.2 PCR product purification

[0150] a. Equilibrate the DNA purification magnetic beads at room temperature for 30 minutes and mix thoroughly on a vortex machine;

[0151] b Prepare 80% ethanol in a ratio of 8:2 for use;

[0152] c. Add 90 μL of DNA purification magnetic beads to each ligation product, mix well by pipetting, incubate at room temperature for 5 minutes, place on a magnetic rack, and discard the supernatant after the solution is clarified; wash with freshly prepared 80% ethanol, discard the supernatant, and repeat this step once; dry, elute with 32 μL of elution buffer, aspirate 30 μL of supernatant for quality control, and sequence on the machine.

[0153] 6. Analysis of sequencing data:

[0154] The raw data was first filtered using fastQC to remove low-quality sequences (phred33 score ≤ 20) and adapter sequences and polyA / T sequences in the reads. The filtered high-quality reads were mapped to the hg38 human genome using BSMAP, and reads with high mapping quality were screened out. After removing PCR duplicates using picard, reads mapped to the target genomic region (the region corresponding to the DNA methylation marker) were selected using samtools and the methylation levels of each DNA methylation marker were calculated.

[0155] The detection performance of the determined methylation markers and the combination for distinguishing liver cancer tissues from non-cancer tissues is shown in the following table:

[0156] Methylation markers Specificity Sensitivity chr2:63053864-63054353 0.918 0.878

[0157] Example 3: Detection performance of the screened markers in liver cancer blood samples

[0158] 414 clinical blood samples were collected, including 218 blood samples from patients with primary liver cancer, 173 blood samples from patients with benign liver diseases, and 23 blood samples from healthy people. The blood samples were subjected to free DNA extraction, methylation conversion, and targeted methylation sequencing according to the method described in Example 2, and the methylation level of each methylation marker was calculated.

[0159] Blood sample statistical results:

[0160] Sample Group Sample Type Detection object Number of samples Detection Methods Hepatocellular carcinoma Blood samples Free DNA 218 Targeted Sequencing-Small Panel Small liver cancer Blood samples Free DNA 5 Targeted Sequencing-Small Panel Benign liver disease Blood samples Free DNA 173 Targeted Sequencing-Small Panel Healthy people Blood samples Free DNA 23 Targeted Sequencing-Small Panel

[0161] Single factor statistical analysis was performed on single methylation markers to calculate the detection performance of ex vivo blood samples for distinguishing liver cancer patients from controls. The sensitivity and specificity of liver cancer detection of the determined methylation markers are shown in the following table:

[0162] Methylation markers Specificity Sensitivity chr2:63053864-63054353 0.903 0.812

[0163] like Figure 2 As shown, the AUC value of the determined methylation marker for methylation sequencing detection of liver cancer ex vivo blood samples was 0.913.

[0164] Example 4: Performance of the identified methylation markers in a liver cancer ex vivo blood sample qPCR detection dataset

[0165] This embodiment provides a primary liver cancer diagnostic reagent, which specifically includes the following nucleic acid combinations for detecting CpG methylation in the chr2:63053864-63054353 gene region: nucleic acid combination 1, nucleic acid combination 2, nucleic acid combination 3, nucleic acid combination 4, nucleic acid combination 5 and nucleic acid combination 6.

[0166] Target region and primer probe: PCR detection region and corresponding detection primer probe are as follows: Region 1: chr2: 63053874-63053971, primer probe combination is as follows: F-01: 5'-TTCTCCCACCTATAACCTCT-3' (SEQ ID NO.1)

[0167] R-01: 5'-TGGTAGGTTTAGATTTCGGT-3' (SEQ ID NO. 2)

[0168] P-01: 5'-CTCGACCGCCCGAAAAAATTTC-3' (SEQ ID NO.3)

[0169] Region 2: chr2: 63053953-63054107, primer probe combination is as follows: F-02: 5'-AACACGTCCAACTATAAACG-3' (SEQ ID NO. 4)

[0170] R-02: 5'-TCGAGATTTGGGTTTGTTAG-3' (SEQ ID NO.5)

[0171] P-02: 5'-CTCCCGCCGCTACTTCC-3' (SEQ ID NO.6)

[0172] Region 3: chr2: 63053970-63054089, primer probe combination is as follows: F-03: 5'-TAGGGGTTTGTTCGAGTTTT-3' (SEQ ID NO. 7)

[0173] R-03: 5'-CGCGTAAAAATAATACGCTC-3' (SEQ ID NO.8)

[0174] P-03: 5'-GATTCGCGGCGTTTTCGC-3' (SEQ ID NO.9)

[0175] Region 4: chr2: 63054088-63054212, primer probe combination is as follows: F-04: 5'-CGTTTATAGTTGGACGTGTT-3' (SEQ ID NO. 10)

[0176] R-04: 5'-CGAAAAATACGCACCTAAAC-3' (SEQ ID NO. 11)

[0177] P-04: 5'-GGCGTTTTTCGTTAAGATTCGTTATTTTG-3' (SEQ ID NO. 12) Region 5: chr2: 63054112-63054305, the primer probe combination is as follows: F-05: 5'-CACCCCCACAAAATAATCTC-3' (SEQ ID NO. 13)

[0178] R-05: 5'-GCGTTTTCGTTAAGATTCG-3' (SEQ ID NO.14)

[0179] P-05: 5'-CCCTAAAACCCGAAAAATACGCAC-3' (SEQ ID NO. 15) Region 6: chr2: 63054194-63054326, the primer probe combination is as follows: F-06: 5'-TTTAGGTGCGTATTTTTCGG-3' (SEQ ID NO. 16)

[0180] R-06: 5'-CGACTACCCAATCTATAAACC-3' (SEQ ID NO.17)

[0181] P-06: 5'-GAGGTTGTTCGGGGAAAGGTTTAG-3' (SEQ ID NO.18)

[0182] Internal standard, β-actin gene, primer probe are as follows:

[0183] b-actin-F01:5'-GTGATGGAGGAGGTTTAGTAAGTT-3'(SEQ ID NO.19)

[0184] b-actin-R01:5'-ACCACCACCCAACACACAATAACAAACACA-3'(SEQ ID NO.20)

[0185] b-actin-P01: 5'-CCAATAAAAACCTACTCCTCCCTTAA-3' (SEQ ID NO. 21)

[0186] A total of 79 clinical blood samples were collected in this experiment, including 32 blood samples from patients with primary liver cancer, 32 blood samples from patients with benign liver diseases, and 15 blood samples from healthy people.

[0187] Sample Group Sample Type Detection object Number of samples Detection Methods Hepatocellular carcinoma Blood samples Free DNA 32 qPCR method Benign liver disease Blood samples Free DNA 32 qPCR method Healthy people Blood samples Free DNA 15 qPCR method

[0188] The 79 blood samples collected above were subjected to quantitative methylation qPCR detection, and the qPCR detection Ct value was recorded. The specific experimental steps are as follows:

[0189] 1. Separation of plasma: First, centrifuge the collected 10 mL clinical blood sample at 1600×g for 10 minutes to separate the plasma. Centrifuge the separated plasma at 16000×g for 10 minutes to separate impurities. The purified plasma sample should be stored in a -80℃ refrigerator for future use.

[0190] 2. Free DNA extraction: Use the "Free DNA Extraction Kit" (Cat. No.: C03-2) of Guangzhou Youze Biotechnology Co., Ltd. to extract plasma free DNA from the separated plasma samples.

[0191] 3. Free DNA conversion: Use ZYMO's "EZ-96 DNA Methvlation-Lightning MagPrep" to perform methylation C->T conversion on the extracted free DNA samples.

[0192] 4. Negative and positive controls for methylation quantitative PCR: The negative control is the genomic DNA of the cell line (cell line: QSG-7701) transformed by the ZYMO kit, with a concentration of 1 ng / μL. After transformation, the C in the negative control is converted to T. The positive control is the genomic DNA of the cell line (cell line: HepG2) converted by the ZYMO kit with bisulfite, with a concentration of 1 ng / μL. After transformation, the C at the methylated CpG position does not change, and the C at other positions is converted to T.

[0193] 5. Reaction system for methylation quantitative PCR:

[0194] Components concentration Volume (μL) Target site-upstream primer F 10μM 1 Target site-fluorescent probe P 10μM 0.5 Target site-downstream primer R 10μM 1 Internal standard site-upstream primer F 10μM 1 Internal standard site-fluorescent probe P 10μM 0.5 Internal standard site-downstream primer R 10μM 1 Reaction buffer 10X 2.5 DNA polymerase 5U / μL 1 dNTPs 2.5mM 2 Free DNA to be tested About 1ng / μL 4 water / 5.5 total / 20

[0195] 6. Reaction procedure of methylation quantitative PCR:

[0196]

[0197] 7. On-machine detection: Mix the sample DNA to be tested, negative reference, and positive reference according to the reaction system of methylation quantitative PCR in step 5. Put the sample into Shanghai Hongshi SLAN-96S quantitative PCR instrument, and set up the quantitative PCR instrument according to the program conditions in step 6 for detection, and collect the fluorescence values ​​of each channel of HEX / ROX / FAM / CY5.

[0198] 8. Result recording: After the methylation quantitative PCR reaction is completed, the threshold is set at the inflection point of the S-type amplification curve to obtain the Ct value of the sample to be tested at the methylation site.

[0199] 9. Quality control: Negative and positive references are tested simultaneously in each test. The negative control is the transformed cell genomic DNA (cell line: QSG-7701) containing the β-actin gene and the low-methylation target gene sequence, and the positive control is the transformed cell cfDNA (cell line: HepG2) containing the β-actin gene and the high-methylation target gene sequence, with a concentration of 1ng / μL. When the negative reference is not amplified, the Ct value of the positive reference is between 28-32, and the Ct value of the internal reference gene is less than 38, the experiment is valid and the next step of sample result determination can be carried out. Otherwise, the result is invalid and the test must be repeated.

[0200] 10. Result determination: If the Ct value of the target marker is less than 35, the test result is positive, otherwise the test result is negative.

[0201] The Ct values ​​of qPCR detection in ex vivo blood samples using the designed primer-probe combination were used to distinguish liver cancer and non-cancer samples. The detection performance is shown in the following table.

[0202] Markers Primer probe combination Specificity Sensitivity chr2:63053864-63054353 Nucleic acid combination 1 0.894 0.781 chr2:63053864-63054353 Nucleic Acid Combination 2 0.915 0.781 chr2:63053864-63054353 Nucleic acid combination 3 0.894 0.813 chr2:63053864-63054353 Nucleic acid combination 4 0.915 0.781 chr2:63053864-63054353 Nucleic acid combination 5 0.915 0.813 chr2:63053864-63054353 Nucleic acid combination 6 0.915 0.813

[0203] From the blood qPCR test results, it can be seen that the liver cancer detection performance of different primer probe combinations designed for the chr2:63053864-63054353 marker is similar, with a specificity of 89.4-91.5% and a sensitivity of 78.1-81.3%. Compared with traditional liver cancer screening methods, this single methylation marker has ideal detection performance, is easy to use and has low cost, which is of great significance for the popularization and promotion of early screening and treatment of liver cancer.

[0204] Finally, it should be noted that the above description is only a preferred embodiment of the present invention and is not intended to limit the protection scope of the present invention. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.

Claims

1. A reagent for detecting the methylation level of a molecular marker, characterized in that: The molecular marker is a nucleic acid molecule containing at least one CpG site in the chr2:63053864-63054353 genomic region sequence; The genomic regions are from the hg38 human reference genome.

2. A reagent for detecting the methylation level of a molecular marker according to claim 1, characterized in that: The molecular marker is located in the following regions containing at least one CpG site: region 1, region 2, region 3, region 4, region 5, and region 6; The region 1 is selected from chr2: 63053874-63053971; the region 2 is selected from chr2: 63053953-63054107; the region 3 is selected from chr2: 63053970-63054089; the region 4 is selected from chr2: 63054088-63054212; the region 5 is selected from chr2: 63054112-63054305; the region 6 is selected from chr2: 63054194-63054326.

3. A reagent for detecting the methylation level of a molecular marker according to claim 2, characterized in that: The reagent includes any one of the nucleic acid combination 1 for detecting the area 1, the nucleic acid combination 2 for detecting the area 2, the nucleic acid combination 3 for detecting the area 3, the nucleic acid combination 4 for detecting the area 4, the nucleic acid combination 5 for detecting the area 5, and the nucleic acid combination 6 for detecting the area 6.

4. A reagent for detecting the methylation level of a molecular marker according to claim 3, characterized in that: The nucleic acid combination 1 includes a primer combination 1, the nucleic acid combination 2 includes a primer combination 2, the nucleic acid combination 3 includes a primer combination 3, the nucleic acid combination 4 includes a primer combination 4, the nucleic acid combination 5 includes a primer combination 5, and the nucleic acid combination 6 includes a primer combination 6; The base sequence of the primer combination 1 has at least 90% identity with the base sequence shown in SEQ ID NO.1-2; The base sequence of the primer combination 2 has at least 90% identity with the base sequence shown in SEQ ID NO.4-5; The base sequence of the primer combination 3 has at least 90% identity with the base sequence shown in SEQ ID NO.7-8; The base sequence of the primer combination 4 has at least 90% identity with the base sequence shown in SEQ ID NO.10-11; The base sequence of the primer combination 5 has at least 90% identity with the base sequence shown in SEQ ID NO.13-14; The base sequence of the primer combination 6 has at least 90% identity with the base sequence shown in SEQ ID NO.16-17.

5. A reagent for detecting the methylation level of a molecular marker according to claim 4, characterized in that: The nucleic acid combination 1 further includes probe 1, the nucleic acid combination 2 further includes probe 2, the nucleic acid combination 3 further includes probe 3, the nucleic acid combination 4 further includes probe 4, the nucleic acid combination 5 further includes probe 5, and the nucleic acid combination 6 further includes probe 6; The base sequence of the probe 1 has at least 90% identity with the base sequence shown in SEQ ID NO.3; The base sequence of the probe 2 has at least 90% identity with the base sequence shown in SEQ ID NO.6; The base sequence of the probe 3 has at least 90% identity with the base sequence shown in SEQ ID NO.9; The base sequence of the probe 4 has at least 90% identity with the base sequence shown in SEQ ID NO.12; The base sequence of the probe 5 has at least 90% identity with the base sequence shown in SEQ ID NO.15; The base sequence of the probe 6 has at least 90% identity with the base sequence shown in SEQ ID NO.

18.

6. A detection product for non-diagnostic purposes of primary hepatocellular carcinoma, characterized in that: The detection product comprises the reagent according to any one of claims 1-5.

7. A detection product for non-diagnostic purposes of primary hepatocellular carcinoma according to claim 6, characterized in that: The detection product also includes any one of a kit, a chip and a sequencing library.

8. A detection kit for non-diagnostic purposes of primary hepatocellular carcinoma, characterized in that: The method comprises the nucleic acid combination of the CpG island site according to any one of claims 3 to 5, a positive control substance, a negative control substance, a detection primer of an internal reference gene, a detection probe of an internal reference gene, a DNA polymerase and a buffer.

9. A detection kit for non-diagnostic purposes of primary hepatocellular carcinoma according to claim 8, characterized in that: The detection samples of the kit are ex vivo blood samples or ex vivo tissue samples and ex vivo leukocyte samples.

Citation Information

Patent Citations

  • Method for assessing prognosis or risk stratification of liver cancer by using cpg methylation variation in gene

    CN111386352A

  • Reagent combination and kit for detecting liver cancer and application of reagent combination and kit

    CN112280865A

  • Marker gene composition for detecting liver cancer, kit and application

    CN116676390A

  • OTX1 methylation marker for detecting liver cancer

    WO2023082142A1

Cited By

  • Three-differential methylation marker composition for detecting liver cancer / early-stage liver cancer and application of three-differential methylation marker composition

    CN119530386A

  • Three-differentiated methylation marker composition for detecting liver cancer / early liver cancer and application thereof

    CN119530386B